Xlife Sciences AG
SIX:XLS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.3
51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Xlife Sciences AG
Xlife Sciences AG
Cost of Revenue
Xlife Sciences AG
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Xlife Sciences AG
SIX:XLS
|
Cost of Revenue
-CHf539.4k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Cost of Revenue
-CHf398.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-13%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Cost of Revenue
-CHf952.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Cost of Revenue
-CHf4.7B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
Tecan Group AG
SIX:TECN
|
Cost of Revenue
-CHf653.3m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Cost of Revenue
-CHf79.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-456%
|
CAGR 10-Years
N/A
|
|
Xlife Sciences AG
Glance View
Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company is headquartered in Zurich, Zuerich and currently employs 19 full-time employees. The company went IPO on 2019-09-30. The firm focuses on investing in technologies in the life science industry. The company supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The firm offers its investors direct access to the further development of technologies at a very early stage. The firm cooperates with industrial partners and universities.
See Also
What is Xlife Sciences AG's Cost of Revenue?
Cost of Revenue
-539.4k
CHF
Based on the financial report for Dec 31, 2023, Xlife Sciences AG's Cost of Revenue amounts to -539.4k CHF.
What is Xlife Sciences AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-8%
Over the last year, the Cost of Revenue growth was 36%. The average annual Cost of Revenue growth rates for Xlife Sciences AG have been -8% over the past three years .
You don't have any saved screeners yet
